Founded three years ago to develop a drug program targeting selective isoforms of phosphatidylinositol 3 (PI3) kinase, Seattle-based Calistoga Pharmaceuticals Inc. has pulled in its second major round of venture funding, adding $30 million for clinical testing in cancer and inflammatory disease. Despite a tough financing environment, Calistoga, turned mainly to its existing investors--Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners. …
No comments:
Post a Comment